芒果苷片薄膜包衣工艺的研究

目的：探讨芒果苷片薄膜包衣工艺的最佳工艺参数。方法：采用比较法和正交试验设计法，以包衣片外观合格率、硬度、增重、耐湿度、溶出度等作为考核指标，确定薄膜包衣的最佳工艺参数。结果：最佳包衣工艺参数为：包衣液浓度为13％，主机转速为12r·min^-1，片床温度45℃。结论：此工艺稳定可行。     

加替沙星薄膜衣片的处方优化及稳定性研究

目的 优选加替沙星薄膜包衣片的处方。方法 采用正交试验设计进行素片和包衣材料的处方优化，并进行稳定性考察。结果素片崩解时限最佳处方是以6％羧甲基淀粉钠为崩解剂、玉米淀粉与微晶纤维素配比1：2、以8％聚乙烯吡咯烷酮为粘合剂，包衣片最佳处方是以4％羟丙基甲基纤维素为成膜材料、溶剂中乙醇与水的配比75：25、以邻苯二甲酸二乙酯为增塑剂。结论优化的包衣片处方可提高素片的稳定性，减少外界湿度的影响。     

泮托拉唑钠片的薄膜包衣工艺改进

目的解决泮托拉唑钠片的薄膜包衣工艺问题。方法采用正交试验法对泮托拉唑钠片的薄膜包衣工艺进行优化改进。结果经片面外观检查,外观合格率达100％。结论经优化改进的工艺完全可行。     

硫酸亚铁片的薄膜包衣工艺改进

目的对硫酸亚铁片的薄膜包衣工艺进行改进。方法采用正交试验法对硫酸亚铁片的薄膜包衣工艺进行优化改进。结果经片面外观检查,外观合格率达100％。结论经优化改进的工艺完全可行。     

盐酸二甲双胍缓释片处方筛选及工艺研究

对盐酸二甲双胍缓释片的处方及工艺进行筛选和研究。方法：根据释放度作为判断原则，对缓释骨架材料、填充剂、粘合剂、润滑剂及包衣材料的种类、规格、用量及工艺等进行了考察，并在此基础上采用正交试验1．9(3^4)方案对处方进行筛选。结果：以HPMC K100M及HPMC K15M作为盐酸二甲双胍缓释片的基本骨架材料，微晶纤维素作为填充剂，硬脂酸镁为润滑剂，4％HPMCE5的70％乙醇溶液适量作为粘合剂制成片芯，采用薄膜包衣法，以欧巴代的70％乙醇溶液作为薄膜包衣材料，制得盐酸二甲双胍缓释骨架片。结论：本制剂工艺简单，所用各种辅料均为国产化，成本低，制得盐酸二甲双胍缓释片释放度符合规定。     

正交法选择羚羊感冒片薄膜包衣的工艺条件

目的：通过对羚羊感冒片薄膜包衣工艺的研究,确定其最佳工艺条件.方法：采用正交试验法,选择包衣液浓度、流量、素片水分及硬度作为考察因素,以崩解、包衣合格率作为指标,选用L9（34）正交表进行试验,筛选出羚羊感冒片薄膜包衣的最佳包衣工艺.结果：确立了羚羊感冒片的薄膜包衣工艺条件.结论：该包衣工艺科学合理,能使产品质量保持稳定,为羚羊感冒片的薄膜包衣的最佳工艺.     

牛黄化毒片薄膜包衣工艺研究

目的：优选牛黄化毒片薄膜包衣的最佳工艺条件。方法：选定包衣液的浓度、片床温度、包衣液流量和包衣锅转速四个因素进行正交方法考查,以包衣片外观合格率为考查指标,用L9（34）正交表进行试验研究,优选出最佳包衣工艺。结果：最佳工艺条件为包衣液的浓度为6%,片床温度为40～50℃,包衣液流量为110 ml/min,包衣锅转速为4～6r/min。结论：该包衣工艺科学合理,生产效率高,为牛黄化毒片的最佳包衣工艺。     

胃溶型银杏叶薄膜包衣片处方和质量研究

目的制备胃溶型银杏叶薄膜包衣片并考察处方与质量。方法以性状、重量差异、崩解时限、硬度、脆碎度、含量为指标因素,根据辅料相容性结果,采用正交设计试验,筛选最优处方,并进行质量考察。结果根据选定的优化处方和工艺制备的胃溶型银杏叶薄膜包衣片及片芯问题得到改善,质量符合药典规定要求。结论优选的胃溶型银杏叶薄膜包衣片处方工艺合理,成品质量符合要求。     

压制包衣法制备二甲双胍脉冲缓释片

目的探讨制备二甲双胍脉冲缓释片的方法。方法以羟丙基甲基纤维素(HPMC)为包衣材料,采用压制包衣法制备二甲双胍脉冲片;正交实验优选处方,对最优处方进行体外释放度验证。结果采用压制包衣法可制备出缓释效果很好的脉冲片,缓释片时滞为5h。结论用压制包衣法制出的二甲双胍缓释片处方设计和工艺可行,质量稳定。     

环丙沙星片薄膜包衣制备工艺研究

目的：探讨环丙沙星片薄膜包衣的优良工艺。方法：使用L9（34）正交试验筛选包衣液浓度、喷液流量、片床温度和包衣锅转速4个工艺对薄膜包衣的影响,探讨环丙沙星片薄膜包衣制作优良工艺。结果：以10%浓度LE薄膜包衣剂,预热时间为6min,喷液流量为10g/min,片床温度为50℃,包衣锅转速为7r/min进行包衣滚筒制作的片剂外观和增重符合规定要求。结论：通过正交试验,能够获得环丙沙星薄膜包衣制备的最佳工艺流程。     

甲花片处方及制粒工艺研究

目的:研究甲花片处方及制粒工艺。方法:以颗粒外观、制粒难易程度、颗粒成型率为指标,采用单因素试验考察流化床制粒工艺;以原料粒度、黏合剂浓度、黏合剂用量为指标,以粒度、休止角、颗粒强度、硬度、脆碎度、崩解时限的综合评分为指标,采用正交试验优选甲花片处方。结果:流化床制粒的最佳工艺为物料温度49～53℃、喷雾压力0.10～0.12MPa、蠕动泵转速度30～38r·min-1;甲花片最佳处方为干膏粉粒度80目、黏合剂浓度3%、黏合剂用量为干膏粉重量的180%～200%。结论:采用流化床制粒法并对处方和工艺进行定量化控制,可以得到质量合格的制剂。     

包衣工艺对布地奈德结肠定位片控释衣膜的影响

目的:优化布地奈德结肠定位片控释衣膜的包衣工艺。方法:采用单因素试验考察喷枪位置、喷液速度、喷气雾化压力、片床温度、进风温度及进风流量等包衣参数对定位片微孔型半透膜和肠溶膜包衣的影响。结果:确定喷枪口离片床距离约10～20cm;微孔型半透膜及肠溶膜包衣液的喷射速度分别为3、1mL·min-1,喷气雾化压力分别为2、1.5bar(1bar=105Pa),进风温度分别为50～55、40～45℃,片床温度分别为(40±1)、(30±1)℃,进风流量分别为5、7m3·min-1;采用优化的包衣参数制得的布地奈德结肠定位片半透膜包衣增重10%,肠溶膜包衣增重5%,24h体外累积释放度为(77.5±8.6)%,释药时滞为(6.0±0.5)h。结论:优化后的包衣工艺适合布地奈德结肠定位片控释衣膜包衣。     

全水型薄膜包衣预混剂在复方丹参片生产中的应用研究

目的研究全水型薄膜包衣技术在复方丹参片生产中的应用,提高复方丹参片的质量稳定性。方法进行加速试验,比较复方丹参片全水型薄膜衣片与醇溶性薄膜衣片的综合质量和稳定性。结果全水型薄膜包衣片外观明显优于醇溶性薄膜衣片,在稳定性考察过程中含量测定和崩解时限均无明显变化。结论全水型薄膜包衣预混剂可用于复方丹参片的包衣生产。     

Metabolic fate of carteolol hydrochloride (OPC-1085), a new beta-adrenergic blocking agent. (6) Pharmacokinetics of carteolol in the rat, dog, rabbit and man]

The kinetics (absorption, distribution and excretion) of carteolol were investigated after oral and intravenous administration to man, rats, Beagle dogs and rabbits. The half-life of carteolol in plasma was 1.22 approximately 1.45 hr in rats, 1.73 approximately 2.08 hr in dogs and 1.42 approximately 1.43 hr in rabbits, and was independent of the route of administration. The absorption rate constants, obtained from log(C1-C) approximately time plot, after oral administration were 1.89 hr-1 in rats, 1.04 hr-1 in dogs and 1.54 hr-1 in rabbits. There were no differences between tablet and film coated tablet in the pharmacokinetic parameters of carteolol in man after oral 30 mg (tablet or film coated tablet) administration [half life (t1/2)=4.50 hr (tablet), 4.30 hr (film coated tablet), elimination rate constant (k2) equals 0.154 hr-1 (tablet), 0.161 hr-1 (film coated tablet)]. The elimination rate constant, obtained from Sigma-minus plot after 2, 5 and 10 mg oral administration, was 0.137 approximately 0.160 hr-1.     

磷酸川芎嗪片薄膜包衣工艺的探讨

目的 探讨采用包衣预混剂对磷酸川芎嗪片进行薄膜包衣的最佳工艺条件.方法 通过正交优化试验法进行试验,对影响包衣过程中包衣液的浓度、包衣片增重、喷雾速度、雾化压力4个因素进行考察,以加速试验后包衣片增重为考核指标进行考核.结果 选用自制的包衣料,加溶液配成5％的包衣溶液,包衣增重2.5％,喷雾速度350 g/min,雾化压力0.5MPa.结论 此制备工艺可行.     

Optimization and pharmacotechnical evaluation of compression‐coated colon‐specific drug delivery system of triphala using factorial design

The purpose of the present investigation was to achieve successful delivery specifically to the colon using guar gum as a compression coat over a core tablet of triphala. In this study, guar gum along with hydroxy propyl methyl cellulose (HPMC) was used as a compression‐coating polymer. The drug delivery system was based on the gastrointestinal transit time concept, assuming colon arrival time to be 6 h. Rapidly disintegrating core tablets containing 100‐mg triphala extract were compression coated with guar gum and HPMC. A 3² full factorial design was applied for optimization of the formulation. Both variables, the proportion of guar gum in polymer blend (X₁) and coat weight of the tablet (X₂), had an influence on the percent drug release after 4 h of dissolution of tablet in the presence of rat cecal content (Y240) and difference in percent drug release between 4 h and 10 h of dissolution of tablet in the presence of rat cecal content (YD).The results revealed that for protecting the rapidly disintegrating core of triphala in the physiological conditions of stomach and upper intestine, the core tablet should be coated with 50% of guar gum in coat formulation and higher coat weight. The proportion of guar gum exhibited predominant action as compared to coat weight. In vivo performance was assessed via an x‐ray roentgenography study by placing barium sulfate as an x‐ray opaque material instead of triphala. The guar gum–HPMC coating was found to be a promising drug delivery system for drugs such as triphala and sennosides to be delivered to the colon. Drug Dev. Res. 65:34–42, 2005. © 2005 Wiley‐Liss, Inc.     

星点设计-效应面法优化复方氯雷伪麻缓释片的缓释片芯处方

目的:优化复方氯雷伪麻缓释片的缓释片芯处方。方法:以氯雷他定加入包衣层并包衣硫酸伪麻黄碱片芯制备复方氯雷伪麻缓释片。采用星点设计-效应面法优化硫酸伪麻黄碱片芯处方,以单硬脂酸甘油酯(GM)和羟丙甲纤维素(HPMC)K15M用量为考察因素,以硫酸伪麻黄碱1、6、12 h的累积释放度为指标,通过重叠等高线图确定优化处方,并进行处方验证。结果:氯雷他定与欧巴代包衣粉按1∶3比例混合包衣成为速释层;硫酸伪麻黄碱片芯作为缓释层,其处方为每100片(600 mg/片)含硫酸伪麻黄碱12 g、GM 16.72 g、HPMC K15M 20.95 g、微晶纤维素9.73 g、硬脂酸镁0.6 g。优化处方所制制剂中氯雷他定15 min的累积溶出度为87.2%,硫酸伪麻黄碱1、6、12 h的累积释放度分别为34.20%、74.32%、94.60%。结论:缓释片芯处方合理、可行,所制备的复方氯雷伪麻缓释片具有缓释作用。     

胸腺肽α1结肠释放片的制备及其体外释药研究

目的:制备胸腺肽α1结肠释放片(Tα1片),评价其体外释药性能。方法:将Tα1制成片芯,2次包衣,内层为壳聚糖盐酸盐,外层为尤特奇L100-55。高效液相色谱(HPLC)法进行含量及含量均匀度测定,扫描电镜法评价壳聚糖盐酸盐包衣膜在模拟大肠液中的降解作用。以荧光剂FD-4为模型化合物,同法制备模拟结肠片,荧光分光光度法检测其在pH 1.2盐酸溶液,pH 6.8磷酸盐缓冲液及模拟大肠液中的体外释放性能。结果:Tα1片的含量及含量均匀度符合《中国药典》相关规定;电镜扫描结果表明,壳聚糖盐酸盐包衣膜在模拟大肠液中具有显著降解作用;模拟结肠片在pH 1.2盐酸溶液和pH 6.8磷酸盐缓冲液中的累积释药量6 h内小于23％,而在模拟大肠液中4 h基本释药完全。结论:本研究所制备的Tα1结肠释放片具有潜在的结肠靶向释药效果。     

Film coated tablets (ColoPulse technology) for targeted delivery in the lower intestinal tract: influence of the core composition on release characteristics

The design of a film coating technology which allows a tablet to deliver the drug in the ileocolonic segment would offer new treatment possibilities. The objective is to develop a platform technology that is suitable for a broad range of drug compounds. We developed a coated tablet with a delayed, pulsatile release profile based on a pH-sensitive coating technology (ColoPulse). The production process was validated, and the effect of core composition on the in vitro release and water uptake investigated. The release profile of the standard tablet core composition, based on the use of cellulose as a filler, was independent of the coat thickness in a range of 9.0-13.2?mg/cm(2). The release profile of a coated tablet was strongly influenced when cellulose was partly replaced by the model substance glucose (loss of sigmoidal release), citric acid (stabilization), sodium bicarbonate (destabilization) or sodium benzoate (destabilization). The film coating takes up water when below the pH-threshold. However, this did not cause early disintegration of the coating. The ColoPulse technology is successfully applied on tablets. The in vitro release characteristics of the coated tablets are influenced by the composition of the core.